Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxyzine + Varenicline for Smoking Cessation
NCT04188106Phase 4Completed
- Sponsor
- Rose Research Center
- Start
- Jun 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of hydroxyzine in nicotine dependence, sponsored by Rose Research Center. Primary endpoints: Perceived Stress Scale-10 at 12 weeks, State-Trait Anxiety Inventory at 12 weeks and 1 more. Started Jun 2019; status: completed.
02
Drugs
hydroxyzine
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT04188106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04188106.